An FDA advisory committee will meet next month to discuss an emergency use authorization.<br />The emergency use authorization would be for Pfizer's COVID-19 vaccine.<br />Earlier this week, Pfizer said clinical trials had shown its vaccine to be 95% effective.<br />"While we cannot predict how long the FDA's review will take, the FDA will review the request as expeditiously as possible, while still doing so in a thorough and science-based manner," FDA Commissioner Stephen M. Hahn<br />In October, the Emergency Care Research Institute warned against releasing a vaccine.<br />They said six months of follow-up data on clinical trial participants is needed to move forward.
